EUVIMEDEUVIMED entdecken
Crossref

For adults with high-risk smoldering multiple myeloma (SMM), how does early intervention with monoclonal antibody therapy (daratumumab) compare with active monitoring?

Sera Tort

Cochrane Clinical Answers · 29.06.2026

DOI: 10.1002/cca.4793 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cochrane Clinical Answers, online erschienen am 29.06.2026. Verfasst von Sera Tort. Die Arbeit nennt 6 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Tort, S. (2026). For adults with high-risk smoldering multiple myeloma (SMM), how does early intervention with monoclonal antibody therapy (daratumumab) compare with active monitoring?. Cochrane Clinical Answers. https://doi.org/10.1002/cca.4793

Vancouver

Tort S. For adults with high-risk smoldering multiple myeloma (SMM), how does early intervention with monoclonal antibody therapy (daratumumab) compare with active monitoring?. Cochrane Clinical Answers. 2026. doi:10.1002/cca.4793

BibTeX
@article{Tort2026,
  author = {Tort, Sera},
  title = {For adults with high-risk smoldering multiple myeloma (SMM), how does early intervention with monoclonal antibody therapy (daratumumab) compare with active monitoring?},
  journal = {Cochrane Clinical Answers},
  year = {2026},
  doi = {10.1002/cca.4793}
}
Kostenlos starten →